TP53 and cancer: APR-246 (eprenetapopt) is a representative agent with this mechanism; it induces radiosensitivity in TP53-mutant cancer cells and has been proposed as a promising strategy because it increases tumor cell death, particularly when combined with alpha-particle radiation therapy [99].